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Abstract: Moving Bed Biofilm Reactors (MBBRs) have been recently proposed as a means to enhance the 
removal of organic micropollutants, e.g., pharmaceuticals, during biological wastewater treatment. This study 
presents a comparative assessment of three different types of MBBR in terms of removal of pharmaceuticals, 
including (i) pre-denitrification with single- and multi-stage configurations (MBBR1); (ii) nitrification with 
controlled biofilm thickness (MBBR2); (iii) and for post-denitrification with dosing of two different external 
readily degradable carbon sources. Results obtained in long- and short-term experiments revealed an 
enhancement of biotransformation rate constants – compared to activated sludge process - on average, for a 
major number of micropollutants of approximately ~60% in the post-denitrification MBBR, possibly due to 
cometabolism and the use of high readily degradable carbon sources (ethanol and methanol). Comparison of 
obtained biotransformation kinetics with values from relevant literature for conventional activated sludge 
suggested MBBRs as effective solution for increasing micropollutant removal in municipal wastewater. 
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Introduction 
Numerous organic pollutants, such as pharmaceuticals and personal care products, undergo 
incomplete removal in conventional municipal wastewater treatment plants (WWTP) due to 
design and operational limitations, resulting in their discharge to receiving water bodies at 
trace level. Presently, research has been focusing on the improvement of conventional WWTP 
performance using novel biological treatment systems. Moving bed biofilm reactors 
(MBBRs), as alternative to conventional activated sludge, are based on biofilm growth on 
suspended plastic carriers. Enhanced removal of several pharmaceuticals was accordingly 
observed in aerobic MBBRs (Falås et al., 2012). However, no study has previously attempted 
to comprehensively elucidate micropollutant removal capabilities of MBBRs at different 
stages of the biological treatment train.  
In this study, we investigated different optimization strategies using MBBRs towards the 
removal of 23 commonly detected pharmaceuticals in municipal wastewater under different 
operational conditions. We assessed the impact of (i) biofilm thickness in nitrifying MBBRs; 
and (ii) organic carbon quality and availability in anoxic pre- and post-denitrifying MBBRs. 
Assessed biotransformation kinetics of the targeted pharmaceuticals were compared to 
relevant literature for activated sludge, thus identifying potential benefits in the employment 
of MBBRs towards the removal of micropollutants 
 
Material and Methods 
Three laboratory-scale MBBR systems were operated with continuous-flow feeding of 
municipal wastewater from local WWTPs under conditions of pre-denitrification (MBBR1), 
nitrification (MBBR2) and post-denitrification (MBBR3). Details of the operational 
conditions are presented in Table 1. In MBBR1, denitrification and biotransformation of 
micropollutants were evaluated in a single-stage and a three-stage MBBR configuration 
where the biofilm was exposed to a decreasing gradient of influent organic carbon loading 
and degradability. The influence of biofilm thickness (ranging between 50 and 500 µm) was 
studied in nitrifying MBBR2 using novel Z-carriers, which allowed for the development of 
biofilm of defined thickness. In MBBR 3, two commonly dosed carbon sources (methanol 
and ethanol) were compared in parallel post-denitrifying MBBRs. Biokinetics of 
(de)nitrification and micropollutant biotransformation rate constants (kBio, L g
-1
 d
-1
) were 
estimated from batch experimental results using Activated Sludge Models (ASMs) and ASM 
for Xenobiotics (ASM-X) (Plósz et al., 2012), respectively. 
Results and Conclusions 
In MBBR1 study, the highest and lowest biotransformation kinetics were found in the first 
and the last stage MBBR, respectively (up to 4-fold decrease for selected compounds), which 
correlated with the estimated denitrification rates in the different stages. In MBBR2 study, the 
biotransformation of more than 60% of targeted compounds was enhanced in thicker biofilms 
(>200 µm), while thinner biofilms (~50 µm) resulted in higher biotransformation of the three 
sulfonamide antibiotics and diclofenac. The methanol-dosed MBBR of the MBBR3 study 
exhibited an enhancement of kBio (up to 2.5-fold) for a number of micropollutants (nine out 
23) compared to the ethanol-dosed MBBR. Detailed results of the investigations on MBBR1–
3 are presented in Torresi et al. (2016, 2017) and Polesel (2016). In Figure 1, the range of 
values of kBio obtained for each micropollutant under the conditions tested was reported. A 
general trend of enhanced biotransformation rate constant kBio for a major number of 
micropollutants (~60%) was observed in MBBR3. One of the possible reasons for this 
observation can be found in the addition of high readily degradable carbon sources (ethanol 
and methanol) commonly used in post-denitrification that could be beneficial for the removal 
of a number of micropollutants possibly due the cometabolic effect of the primary substrate. 
When comparing kBio estimated in the three MBBRs with values from relevant literature for 
conventional activated sludge, an improvement of several (but not all) targeted 
micropollutants was shown, e.g., for atenolol, carbamazepine, citalopram, clarithromycin, 
diclofenac. It can be thus concluded that MBBRs represents a suitable technology for the 
optimization of micropollutant removal in municipal wastewater under a range of operating 
conditions (nitrifying, pre- and post-denitrifying). 
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Table 1. Operational conditions of the three MBBR systems, in which pharmaceutical removal was investigated. 
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Diatrizoic acid
Iohexol
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Carbamazepine
Citalopram
Venlafaxine
Erythromycin
Clarithromycin
Roxithromycin
Trimethoprim
Sulfadiazine
Sulfamethizole
Sulfamethoxazole
Acetylsulfadiazine
Sotalol
Metoprolol
Propranolol
Atenolol
MBBR1
MBBR2
MBBR3
*
*
*
*
*
*
*
*
*
*
*
*
CAS (Lit.)
MBBR (Lit.)
kBio (L g
-1
 d
-1
)
 
Figure 1. Summary of biotransformation rate constants (kBio) for targeted pharmaceuticals in MBBR1–3 
and comparison with literature values from conventional activated sludge systems (CAS). Asterisks denote 
pharmaceuticals that were detected in all MBBRs. For a number of compounds, the comparison is reported 
only between MBBR2 and MBBR3 study, as only micropollutants naturally found in pre-clarified 
wastewater were studied in MBBR1. 
 
